GlaxoSmithKline Pharmaceuticals on Monday announced its entry into the oncology space with the launch of precision therapies for gynaecological cancers in India.

The company has introduced two advanced treatments — Jemperli (dostarlimab) and Zejula (niraparib).

“These therapies address a significant unmet need in gynaecological cancers in India and mark an important step forward in women’s cancer care. With this launch, we are reinforcing our long-term commitment to expanding the specialty medicines portfolio in India,” said Bhushan Akshikar, MD, GSK India.